Insulet Corporation
9 Oak Park Drive
Bedford
Massachusetts
01730
United States
Tel: 781-457-5000
Fax: 781-457-5011
Website: http://www.insulet.com/
417 articles about Insulet Corporation
-
Insulet’s Randomized Controlled Trial (OP5-003) Demonstrates Omnipod® 5 Automated Insulin Delivery System is Superior to Pump Therapy
3/8/2024
Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod® brand of products, presented positive results from its first randomized controlled trial showing improved glycemic and patient-reported outcomes in type 1 diabetes with the Omnipod 5 Automated Insulin Delivery System.
-
Insulet to Present Results from First Omnipod® 5 Randomized Controlled Trial (OP5-003) at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)
3/5/2024
Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod® brand of products, will present new clinical evidence related to the Omnipod 5 Automated Insulin Delivery System at the 17th International Conference on Advanced Technologies & Treatments for Diabetes taking place March 6 – 9, 2024 in Florence, Italy, and online.
-
Insulet Reports Full Year 2023 Revenue Increase of 30% (30% Constant Currency1) and Fourth Quarter 2023 Revenue Increase of 38% Year-Over-Year (37% Constant Currency)
2/22/2024
Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod® brand of products, announced financial results for the three months and full year ended December 31, 2023.
-
Insulet to Present at The Raymond James & Associates 45th Annual Institutional Investors Conference
2/13/2024
Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at The Raymond James & Associates 45th Annual Institutional Investors Conference in Orlando on Tuesday, March 5, 2024 at 11:35 a.m. (Eastern Time).
-
Insulet Announces CE Mark Approval of Omnipod® 5 Integration with Abbott FreeStyle Libre 2 Plus Sensor
2/7/2024
Insulet Corporation announced it has received CE mark approval under the European Medical Device Regulation for the added compatibility of the Abbott FreeStyle Libre 2 Plus sensor with Insulet’s Omnipod 5 Automated Insulin Delivery System for individuals aged two years and older with type 1 diabetes.
-
Insulet Announces Changes to Board of Directors with Retirements and New Appointments
1/18/2024
Insulet Corporation announced the following appointments to the Company’s Board of Directors, effective January 18.
-
Insulet to Announce Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024
1/11/2024
Insulet Corporation today announced plans to release its financial results for the fourth quarter and full year of 2023 on February 22, 2024 after the close of the financial markets.
-
Insulet to Present at Upcoming Investor Conferences - November 28, 2023
11/28/2023
Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod® brand of products, announced that management will present at two upcoming investor conferences.
-
Insulet Announces FDA 510(k) Clearance of the Omnipod® 5 App for iPhone
10/23/2023
Insulet Corporation announced it has received FDA 510 clearance for the Omnipod 5 App for iPhone, making Insulet the first and only company to offer a tubeless automated insulin delivery system with full control from a compatible Android and iOS smartphone.
-
Insulet Announces CFO Transition
10/3/2023
Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod® brand of products, announced that Wayde McMillan has decided to step down from his role as Executive Vice President, Chief Financial Officer and Treasurer, effective October 20, 2023.
-
Insulet to Present Extended Real-World Evidence and Best Practices for Optimizing Care with Omnipod® 5
10/2/2023
Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod® brand of products, announced its schedule of events and presentations at EASD 2023, taking place today through October 6 in Hamburg, Germany, and online.
-
Insulet to Announce Third Quarter 2023 Financial Results on November 2, 2023
9/28/2023
Insulet Corporation announced plans to release its financial results for the third quarter of 2023 on November 2, 2023 after the close of the financial markets.
-
Insulet to Present at Upcoming September 2023 Investor Conferences
8/24/2023
Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod® brand of products, announced that management will present at three upcoming investor conferences.
-
Insulet Reports Second Quarter 2023 Revenue Increase of 32% Year-Over-Year (32% Constant Currency1)
8/8/2023
Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod® brand of products, announced financial results for the three months ended June 30, 2023.
-
Insulet to Announce Second Quarter 2023 Financial Results on August 8, 2023
7/5/2023
Insulet Corporation announced plans to release its financial results for the second quarter of 2023 on August 8, 2023 after the close of the financial markets.
-
Insulet Celebrates One Year of Omnipod® 5 at the American Diabetes Association 83rd Scientific Sessions
6/22/2023
Insulet Corporation announced an exciting lineup of events and product developments that will be discussed at the American Diabetes Association 83rd Scientific Sessions in San Diego, California, including new real-world evidence of improved outcomes and optimization of care using the Omnipod 5 Automated Insulin Delivery System.
-
Insulet Announces Omnipod® 5 Automated Insulin Delivery System is Now Available in the United Kingdom
6/20/2023
Insulet Corporation announced the commercial launch of its Omnipod 5 Automated Insulin Delivery System for individuals aged two years and older with type 1 diabetes in the United Kingdom.
-
Insulet Announces New Organizational Structure to Drive Further Growth
5/4/2023
Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod® brand of products, announced its new organizational structure designed to accelerate innovation and commercialization.
-
Insulet Reports First Quarter 2023 Revenue Increase of 21% Year-Over-Year (23% Constant Currency1)
5/4/2023
Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod® brand of products, announced financial results for the three months ended March 31, 2023.
-
Insulet Publishes 2022 Sustainability Report Focused on Innovating for the Future and Preserving the Environment
5/2/2023
Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod® brand of products, released its 2022 Sustainability Report highlighting accomplishments in environmental, social, and governance across its global markets.